TARA vs TCRX

Protara Therapeutics, Inc. vs TScan Therapeutics, Inc. — Valuation Comparison 2026

TARA

Biotechnology
Protara Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$4.75
Last close
Models
7/13
Active
VS

TCRX

Biotechnology
TScan Therapeutics, Inc.
Quality
6.4
out of 10
Value Trap
24
SAFE
Price
$1.08
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType TARA Fair ValueTARA Upside TCRX Fair ValueTCRX Upside
Bayesian DCF Intrinsic $1.39 -70.6% $0.71 -34.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.90 -82.3% $1.66 +53.8%
Dynamic NAV Asset-Based $2.67 -43.8% $2.48 +130.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TARA vs TCRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TARA vs TCRX — Which Stock Is More Undervalued?

TCRX scores higher with a 6.4/10 quality rating vs TARA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protara Therapeutics, Inc. (TARA) and TScan Therapeutics, Inc. (TCRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TARA currently trades at $4.75 with a QOC of 4.1/10, while TCRX trades at $1.08 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).